Regulation of tumor cell chemotaxis by type IV collagen is mediated by a Ca2+-dependent mechanism requiring CD47 and the integrin αvβ3

被引:33
作者
Shahan, TA
Fawzi, A
Bellon, G
Monboisse, JC
Kefalides, NA
机构
[1] Univ Penn, City Sci Ctr, Connect Tissue Res Inst, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA
[3] Univ Reims Champagne Ardenne, Lab Biochim Med & Biol Mol, CNRS, UPRESA 6021,IFR Biomol 53,UFR Med Reims, F-51095 Reims, France
关键词
D O I
10.1074/jbc.275.7.4796
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Studies from our laboratories demonstrated that synthetic peptides from the non-collagenous (NC-1) domain of the (alpha 3 (IV) chain of type TV collagen (COL IV) enhanced tumor cell adhesion (Han, J., Ohno, N., Monboisse, J. C., Pasco, S., Borel, J. P., and Kefalides, N. A. (1997) J. Biol. Chem. 272, 20395-20401). We have isolated the receptors for the alpha 3(IV)185-203 peptide from melanoma and prostate tumor cells and identified them as CD47/integrin-associated protein and the integrin alpha(v)beta(3) (Shahan, T. A, Ziaie, Z., Pasco, S., Fawzi, A, Bellon, G., Monboisse, J. C., and Kefalides, N. A. (1999) Cancer Res. 59, 4584-4590). In the present study we have examined the effect of CD47 and the integrin alpha(v)beta(3) on in vitro tumor cell chemotaxis and Ca-i(2+) modulation in response to COL IV, from the anterior lens capsule (ALC-COL IV) and peptides from its NC-1 domain. COL TV as well as the alpha 3(IV) peptide promoted tumor cell chemotaxis with an immediate increase in intracellular [Ca2+]. Treating tumor cells with CD47 and integrin alpha(v)beta(3)-reactive antibodies reduced chemotaxis as well as the rise in [Ca2+](i) in response to ALC-COL IV or the alpha 3(IV)185-203 peptide but not to Engelbreth-Holm-Swarm-COL IV or fibronectin. The a3(IV)185-203 synthetic peptide stimulated an increase in calcium from intracellular stores exclusively, whereas ALC-COL IV, Engelbreth-Holm-Swarm-COL IV, and fibronectin stimulated Ca2+ flux from both internal and external stores. Furthermore, treatment of the cells with Ca2+ chelator bis-(O-aminophenoxyl)ethane-N,N,N',N' -tetraaceticacid-acetomethoxy ester inhibited chemotaxis toward both ALC-COL IV and the alpha 3(IV)185-203 peptide. These data indicate that CD47 and integrin alpha(v)beta(3) regulate tumor cell chemotaxis in response to COL IV and the alpha 3(IV)185-203 peptide through a Ca2+-dependent mechanism.
引用
收藏
页码:4796 / 4802
页数:7
相关论文
共 39 条
  • [1] FIBRONECTIN AND INTEGRINS IN INVASION AND METASTASIS
    AKIYAMA, SK
    OLDEN, K
    YAMADA, KM
    [J]. CANCER AND METASTASIS REVIEWS, 1995, 14 (03) : 173 - 189
  • [2] INTEGRINS AND OTHER CELL-ADHESION MOLECULES
    ALBELDA, SM
    BUCK, CA
    [J]. FASEB JOURNAL, 1990, 4 (11) : 2868 - 2880
  • [3] Barany G., 1980, PEPTIDES ANAL SYNTHE, V2, P1
  • [4] BRINKER JM, 1985, COLLAGEN REL RES, V5, P233
  • [5] INTEGRIN-ASSOCIATED PROTEIN - A 50-KD PLASMA-MEMBRANE ANTIGEN PHYSICALLY AND FUNCTIONALLY ASSOCIATED WITH INTEGRINS
    BROWN, E
    HOOPER, L
    HO, T
    GRESHAM, H
    [J]. JOURNAL OF CELL BIOLOGY, 1990, 111 (06) : 2785 - 2794
  • [6] TRANSENDOTHELIAL MIGRATION OF NEUTROPHILS INVOLVES INTEGRIN-ASSOCIATED PROTEIN (CD47)
    COOPER, D
    LINDBERG, FP
    GAMBLE, JR
    BROWN, EJ
    VADAS, MA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (09) : 3978 - 3982
  • [7] ACTIN-BINDING PROTEIN REQUIREMENT FOR CORTICAL STABILITY AND EFFICIENT LOCOMOTION
    CUNNINGHAM, CC
    GORLIN, JB
    KWIATKOWSKI, DJ
    HARTWIG, JH
    JANMEY, PA
    BYERS, HR
    STOSSEL, TP
    [J]. SCIENCE, 1992, 255 (5042) : 325 - 327
  • [8] DOWDY S, 1983, STAT RES, P32
  • [9] The recognition sites of the integrins alpha(1)beta(1) and alpha(2)beta(1) within collagen IV are protected against gelatinase A attack in the native protein
    Eble, JA
    Ries, A
    Lichy, A
    Mann, K
    Stanton, H
    Gavrilovic, J
    Murphy, G
    Kuhn, K
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (48) : 30964 - 30970
  • [10] FALK W, 1988, J IMMUNOL METHODS, V33, P33239